NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

There is no need to be rude.

They are not extending the trial. The trial was always meant to go 3 years after the last enrolled patient. They do not, as we have seen, have to data lock the study and do the analysis before it ends. So it's a matter of whether they decide to data lock before the 3 years are up or not. Time will tell what they decide.

As for manufacturing build out, they need that in the event of study success, to get biological market approval. They wouldn't be able to get it if they do not concentrate on commercializations.